Serum Institute of India

Serum Institute of India will retain a minority stake in the company, with SCHOTT Pharma maintaining 50 per cent ownership

Indian Bio-Economy Report 2024 by the Association of Biotechnology Led Enterprises (ABLE) highlights India’s current bioeconomy,…

X-CIPLOG Reunion 2025 and Excellence Awards reflect industry recognition resonating with the government’s padma bhushan honour to…

Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth

Serum Institute of India’s R21/Matrix-M was found to be generally safe and well-tolerated, with no serious adverse events being…

The initial shipment will be sent to the Central African Republic (CAR), followed by other African countries such as South Sudan…

With this investment, SII will acquire a 20 per cent stake in IntegriMedical. Reportedly, the investment is expected to accelerate…

Univercells and SII believe that they may be able to dramatically accelerate the progress of new medicines

BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally

Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78 per…